Literature DB >> 34812647

Administration of aerosolized SARS-CoV-2 to K18-hACE2 mice uncouples respiratory infection from fatal neuroinvasion.

Valeria Fumagalli1,2, Micol Ravà1, Davide Marotta1,2, Pietro Di Lucia1, Chiara Laura1,2,3, Eleonora Sala1,2, Marta Grillo1, Elisa Bono1, Leonardo Giustini1, Chiara Perucchini1, Marta Mainetti1, Alessandro Sessa4, José M Garcia-Manteiga3, Lorena Donnici5, Lara Manganaro5, Serena Delbue6, Vania Broccoli4,7, Raffaele De Francesco5,8, Patrizia D'Adamo4,9, Mirela Kuka1,2, Luca G Guidotti1,2, Matteo Iannacone1,2,10.   

Abstract

The development of a tractable small animal model faithfully reproducing human coronavirus disease 2019 pathogenesis would arguably meet a pressing need in biomedical research. Thus far, most investigators have used transgenic mice expressing the human ACE2 in epithelial cells (K18-hACE2 transgenic mice) that are intranasally instilled with a liquid severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) suspension under deep anesthesia. Unfortunately, this experimental approach results in disproportionate high central nervous system infection leading to fatal encephalitis, which is rarely observed in humans and severely limits this model’s usefulness. Here, we describe the use of an inhalation tower system that allows exposure of unanesthetized mice to aerosolized virus under controlled conditions. Aerosol exposure of K18-hACE2 transgenic mice to SARS-CoV-2 resulted in robust viral replication in the respiratory tract, anosmia, and airway obstruction but did not lead to fatal viral neuroinvasion. When compared with intranasal inoculation, aerosol infection resulted in a more pronounced lung pathology including increased immune infiltration, fibrin deposition, and a transcriptional signature comparable to that observed in SARS-CoV-2–infected patients. This model may prove useful for studies of viral transmission, disease pathogenesis (including long-term consequences of SARS-CoV-2 infection), and therapeutic interventions.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 34812647     DOI: 10.1126/sciimmunol.abl9929

Source DB:  PubMed          Journal:  Sci Immunol        ISSN: 2470-9468


  10 in total

1.  Passive immunization with equine RBD-specific Fab protects K18-hACE2-mice against Alpha or Beta variants of SARS-CoV-2.

Authors:  Mariette Barbier; Katherine S Lee; Mayur S Vikharankar; Shriram N Rajpathak; Nandkumar Kadam; Ting Y Wong; Brynnan P Russ; Holly A Cyphert; Olivia A Miller; Nathaniel A Rader; Melissa Cooper; Jason Kang; Emel Sen-Kilic; Zeriel Y Wong; Michael T Winters; Justin R Bevere; Ivan Martinez; Rachayya Devarumath; Umesh S Shaligram; F Heath Damron
Journal:  Front Immunol       Date:  2022-08-15       Impact factor: 8.786

2.  Identification of Neutrophil-Related Factor LCN2 for Predicting Severity of Patients With Influenza A Virus and SARS-CoV-2 Infection.

Authors:  Zhisheng Huang; Hui Li; Shuai Liu; Ju Jia; Ying Zheng; Bin Cao
Journal:  Front Microbiol       Date:  2022-04-12       Impact factor: 5.640

Review 3.  K18- and CAG-hACE2 Transgenic Mouse Models and SARS-CoV-2: Implications for Neurodegeneration Research.

Authors:  Simona Dedoni; Valeria Avdoshina; Chiara Camoglio; Carlotta Siddi; Walter Fratta; Maria Scherma; Paola Fadda
Journal:  Molecules       Date:  2022-06-28       Impact factor: 4.927

Review 4.  After the virus has cleared-Can preclinical models be employed for Long COVID research?

Authors:  Ethan B Jansen; Spencer N Orvold; Cynthia L Swan; Anthony Yourkowski; Brittany M Thivierge; Magen E Francis; Anni Ge; Melissa Rioux; Joseph Darbellay; John G Howland; Alyson A Kelvin
Journal:  PLoS Pathog       Date:  2022-09-07       Impact factor: 7.464

5.  Impact of Microbiota Depletion by Antibiotics on SARS-CoV-2 Infection of K18-hACE2 Mice.

Authors:  Patrícia Brito Rodrigues; Giovanni Freitas Gomes; Monara K S C Angelim; Gabriela F Souza; Stefanie Primon Muraro; Daniel A Toledo-Teixeira; Bruna Amanda Cruz Rattis; Amanda Stephane Passos; Laís Passarielo Pral; Vinícius de Rezende Rodovalho; Arilson Bernardo Dos Santos P Gomes; Valquíria Aparecida Matheus; André Saraiva Leão Marcelo Antunes; Fernanda Crunfli; Krist Helen Antunes; Ana Paula Duarte de Souza; Sílvio Roberto Consonni; Luiz Osório Leiria; José Carlos Alves-Filho; Thiago M Cunha; Pedro M M Moraes-Vieira; José Luiz Proença-Módena; Marco Aurélio R Vinolo
Journal:  Cells       Date:  2022-08-18       Impact factor: 7.666

6.  SARS-CoV-2 Delta variant induces enhanced pathology and inflammatory responses in K18-hACE2 mice.

Authors:  Katherine S Lee; Ting Y Wong; Brynnan P Russ; Alexander M Horspool; Olivia A Miller; Nathaniel A Rader; Jerome P Givi; Michael T Winters; Zeriel Y A Wong; Holly A Cyphert; James Denvir; Peter Stoilov; Mariette Barbier; Nadia R Roan; Md Shahrier Amin; Ivan Martinez; Justin R Bevere; F Heath Damron
Journal:  PLoS One       Date:  2022-08-29       Impact factor: 3.752

7.  Editorial overview: Viral pathogenesis.

Authors:  Antonio Bertoletti; Matteo Iannacone
Journal:  Curr Opin Virol       Date:  2022-07-08       Impact factor: 7.121

8.  Mouse models of COVID-19 recapitulate inflammatory pathways rather than gene expression.

Authors:  Cameron R Bishop; Troy Dumenil; Daniel J Rawle; Thuy T Le; Kexin Yan; Bing Tang; Gunter Hartel; Andreas Suhrbier
Journal:  PLoS Pathog       Date:  2022-09-26       Impact factor: 7.464

Review 9.  The neuroinvasiveness, neurotropism, and neurovirulence of SARS-CoV-2.

Authors:  Lisa Bauer; Brigitta M Laksono; Femke M S de Vrij; Steven A Kushner; Oliver Harschnitz; Debby van Riel
Journal:  Trends Neurosci       Date:  2022-03-03       Impact factor: 16.978

10.  Fatal Neurodissemination and SARS-CoV-2 Tropism in K18-hACE2 Mice Is Only Partially Dependent on hACE2 Expression.

Authors:  Mariano Carossino; Devin Kenney; Aoife K O'Connell; Paige Montanaro; Anna E Tseng; Hans P Gertje; Kyle A Grosz; Maria Ericsson; Bertrand R Huber; Susanna A Kurnick; Saravanan Subramaniam; Thomas A Kirkland; Joel R Walker; Kevin P Francis; Alexander D Klose; Neal Paragas; Markus Bosmann; Mohsan Saeed; Udeni B R Balasuriya; Florian Douam; Nicholas A Crossland
Journal:  Viruses       Date:  2022-03-05       Impact factor: 5.048

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.